Sera Prognostics, Inc. (NASDAQ:SERA) Insider Sells $105,004.51 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA) insider Robert Gardner Harrison sold 14,209 shares of Sera Prognostics stock in a transaction on Friday, January 10th. The shares were sold at an average price of $7.39, for a total value of $105,004.51. Following the sale, the insider now directly owns 116,837 shares in the company, valued at $863,425.43. The trade was a 10.84 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Robert Gardner Harrison also recently made the following trade(s):

• On Monday, January 13th, Robert Gardner Harrison sold 2,264 shares of Sera Prognostics stock. The shares were sold at an average price of $6.47, for a total value of $14,648.08.

Sera Prognostics Stock Down 0.2 %

SERA stock opened at $6.60 on Friday. The company has a market capitalization of $222.88 million, a P/E ratio of -6.67 and a beta of 0.86. The company has a 50-day simple moving average of $7.40 and a 200 day simple moving average of $7.31. Sera Prognostics, Inc. has a fifty-two week low of $4.98 and a fifty-two week high of $12.35.

Sera Prognostics (NASDAQ:SERA) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.09 million. During the same period in the previous year, the business earned ($0.23) EPS. Equities analysts anticipate that Sera Prognostics, Inc. will post -0.96 EPS for the current year.

Hedge Funds Weigh In On Sera Prognostics

Hedge funds have recently modified their holdings of the company. Bank of New York Mellon Corp lifted its holdings in shares of Sera Prognostics by 100.2% in the second quarter. Bank of New York Mellon Corp now owns 150,708 shares of the company’s stock valued at $892,000 after buying an additional 75,441 shares during the period. Rhumbline Advisers acquired a new stake in Sera Prognostics in the 2nd quarter valued at about $190,000. American Century Companies Inc. boosted its position in shares of Sera Prognostics by 12.7% during the 2nd quarter. American Century Companies Inc. now owns 25,682 shares of the company’s stock valued at $152,000 after purchasing an additional 2,891 shares in the last quarter. Renaissance Technologies LLC acquired a new position in shares of Sera Prognostics in the 2nd quarter worth approximately $162,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Sera Prognostics in the 2nd quarter worth approximately $68,000. 54.64% of the stock is currently owned by institutional investors and hedge funds.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.